Literature DB >> 9329605

Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations.

H Meden1, S Mielke, D Marx, W Wuttke, W Kuhn.   

Abstract

BACKGROUND: In breast and ovarian cancer patients elevated serum levels of the oncoprotein p105 were detected. We examined the influence of endocrine factors on the p105 serum concentration.
MATERIALS AND METHODS: The sera of 115 and non-pregnant women were analysed. Of the premenopausal women (n = 77) hormonal contraception was used by 30 women, and of the postmenopausal women (n = 33) there were 15 women using hormonal replacement therapy (HRT). The serum specimens were analysed by ELISA.
RESULTS: Women with hormonal contraception had significantly lower serum levels than premenospausal controls (82-138 fmol/ml, median 109 fmol/ml vs. 103-183 fmol/ml, median 130 fmol/ml; P < 0.001). In postmenopausal women with HRT serum levels were significantly lower than in postmenopausal controls (88-136 fmol/ml, median 117 fmol/ml vs. 99-261 fmol/ml, median 148 fmol/ml; P < 0.001).
CONCLUSIONS: Sex steroids seem to modulate c-erbB-2 activity. These results are important with regard to clinical studies on p105 oncoprotein in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9329605

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients.

Authors:  Patricia Diana Sørensen; Erik Hugger Jakobsen; Jonna Skov Madsen; Eva Brix Petersen; Rikke Fredslund Andersen; Birthe Østergaard; Ivan Brandslund
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-13       Impact factor: 4.553

Review 2.  [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].

Authors:  C Kleinschnitz; S G Meuth; B C Kieseier; H Wiendl
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

Review 3.  Multiple sclerosis therapy: an update on recently finished trials.

Authors:  Christoph Kleinschnitz; Sven G Meuth; Olaf Stüve; Bernd Kieseier; Heinz Wiendl
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 6.682

4.  Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

Authors:  Abby L Cosentino-Boehm; Jacqueline M Lafky; Tammy M Greenwood; Kimberly D Kimbler; Marites C Buenafe; Yuxia Wang; Adam J Branscum; Ping Yang; Nita J Maihle; Andre T Baron
Journal:  Diagnostics (Basel)       Date:  2013-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.